Synlogic (SYBX) Competitors $1.46 0.00 (-0.27%) As of 12:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SYBX vs. RPTX, INKT, GANX, CVM, COEP, KALA, MNOV, GNTA, INMB, and CUEShould you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include Repare Therapeutics (RPTX), MiNK Therapeutics (INKT), Gain Therapeutics (GANX), CEL-SCI (CVM), Coeptis Therapeutics (COEP), KALA BIO (KALA), MediciNova (MNOV), Genenta Science (GNTA), INmune Bio (INMB), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical products" industry. Synlogic vs. Its Competitors Repare Therapeutics MiNK Therapeutics Gain Therapeutics CEL-SCI Coeptis Therapeutics KALA BIO MediciNova Genenta Science INmune Bio Cue Biopharma Synlogic (NASDAQ:SYBX) and Repare Therapeutics (NASDAQ:RPTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk. Does the media refer more to SYBX or RPTX? In the previous week, Repare Therapeutics had 2 more articles in the media than Synlogic. MarketBeat recorded 2 mentions for Repare Therapeutics and 0 mentions for Synlogic. Repare Therapeutics' average media sentiment score of 1.64 beat Synlogic's score of 0.00 indicating that Repare Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Synlogic Neutral Repare Therapeutics Very Positive Is SYBX or RPTX more profitable? Synlogic's return on equity of -8.09% beat Repare Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SynlogicN/A -8.09% -5.50% Repare Therapeutics N/A -78.25%-66.85% Which has more volatility and risk, SYBX or RPTX? Synlogic has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Repare Therapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Which has stronger valuation & earnings, SYBX or RPTX? Synlogic has higher earnings, but lower revenue than Repare Therapeutics. Synlogic is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynlogic$10K1,703.52-$23.36M-$0.08-18.20Repare Therapeutics$53.48M1.36-$84.69M-$2.58-0.66 Do institutionals and insiders have more ownership in SYBX or RPTX? 63.4% of Synlogic shares are held by institutional investors. Comparatively, 85.1% of Repare Therapeutics shares are held by institutional investors. 3.0% of Synlogic shares are held by insiders. Comparatively, 11.5% of Repare Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate SYBX or RPTX? Repare Therapeutics has a consensus target price of $4.50, suggesting a potential upside of 166.27%. Given Repare Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Repare Therapeutics is more favorable than Synlogic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Repare Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryRepare Therapeutics beats Synlogic on 10 of the 15 factors compared between the two stocks. Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYBX vs. The Competition Export to ExcelMetricSynlogicMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.08M$3.17B$5.79B$9.92BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-18.2521.2175.7326.67Price / Sales1,703.52477.57556.54122.11Price / CashN/A45.1137.1158.92Price / Book1.349.9611.296.07Net Income-$23.36M-$53.47M$3.29B$266.51M7 Day Performance-0.27%2.37%0.62%-0.04%1 Month Performance4.00%8.28%6.94%3.84%1 Year Performance-0.82%13.65%57.33%23.68% Synlogic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYBXSynlogicN/A$1.46-0.3%N/A-1.4%$17.08M$10K-18.2580RPTXRepare Therapeutics3.496 of 5 stars$1.58-0.6%$4.50+184.8%-39.0%$68.31M$250K-0.61180News CoveragePositive NewsHigh Trading VolumeINKTMiNK Therapeutics1.777 of 5 stars$14.57-2.2%$37.50+157.4%+72.0%$67.39MN/A-5.0630Negative NewsShort Interest ↑GANXGain Therapeutics3.1136 of 5 stars$1.84-6.6%$7.80+323.9%+67.3%$66.15MN/A-2.9220News CoveragePositive NewsHigh Trading VolumeCVMCEL-SCI0.3742 of 5 stars$10.56+10.9%N/A-65.1%$65.52MN/A-22.0043Short Interest ↑COEPCoeptis Therapeutics1.4616 of 5 stars$13.65+1.4%N/A+203.2%$64.88MN/A-2.352Short Interest ↓Gap UpKALAKALA BIO2.8659 of 5 stars$8.78-4.7%$13.00+48.1%+141.4%$64.66M$3.89M-1.2930Trending NewsAnalyst UpgradeAnalyst RevisionGap DownMNOVMediciNova1.942 of 5 stars$1.32+0.6%$7.00+430.3%-24.0%$64.37M$1M-5.2810GNTAGenenta Science2.7696 of 5 stars$3.50-0.4%$25.00+615.3%-13.6%$64.20MN/A0.007Gap UpHigh Trading VolumeINMBINmune Bio2.2008 of 5 stars$2.24-7.1%$18.40+721.4%-68.8%$64.07M$50K-0.9010CUECue Biopharma1.3316 of 5 stars$0.82-0.9%N/A+18.8%$63.47M$9.29M-1.4660High Trading Volume Related Companies and Tools Related Companies Repare Therapeutics Competitors MiNK Therapeutics Competitors Gain Therapeutics Competitors CEL-SCI Competitors Coeptis Therapeutics Competitors KALA BIO Competitors MediciNova Competitors Genenta Science Competitors INmune Bio Competitors Cue Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYBX) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synlogic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
